ANIP
VENTE TOTALE: 5 400 titres (~401 220,00 $ US)
- Insiders
- Lalwani Nikhil
- Total bought
- —
- Total sold
- $401,220
- Last activity
- 2026-08-25
- Last synced
-
2026-08-31 10:14:36
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-29
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 51.0% | 59.3% | 62.7% | 56.1% | 53.5% | |
| Ebit Margin | 13.1% | -0.8% | 9.6% | -10.9% | -20.4% | |
| Ebitda Margin | 23.5% | 10.3% | 21.9% | 7.9% | 1.4% | |
| Operating Profit Margin | 9.2% | 0.1% | 9.6% | -11.2% | -18.4% | |
| Pretax Profit Margin | 10.8% | -3.6% | 4.1% | -19.8% | -25.9% | |
| Continuous Operations Profit Margin | 8.9% | -3.0% | 3.9% | -15.1% | -19.7% | |
| Net Profit Margin | 8.9% | -3.0% | 3.9% | -15.1% | -19.7% | |
| Bottom Line Profit Margin | 8.0% | -3.3% | 3.5% | -15.7% | -19.8% | |
| Current Ratio | 2.708 | 2.725 | 3.573 | 3.462 | 3.676 | |
| Quick Ratio | 2.194 | 2.018 | 2.809 | 2.403 | 2.743 | |
| Solvency Ratio | 0.189 | 0.058 | 0.176 | 0.028 | 0.011 | |
| Cash Ratio | 1.027 | 0.748 | 1.520 | 0.485 | 1.146 | |
| Price To Earnings Ratio | 22.554 | -53.154 | 58.042 | -13.190 | -13.553 | |
| Price To Earnings Growth Ratio | -0.052 | 0.254 | -0.443 | 1.281 | -0.168 | |
| Forward Price To Earnings Growth Ratio | -0.052 | 0.254 | -0.443 | 1.281 | -0.168 | |
| Price To Earnings Diluted Ratio | 23.777 | -53.154 | 58.660 | -13.190 | -13.553 | |
| Price To Earnings Diluted Growth Ratio | -0.057 | 0.252 | -0.448 | 1.281 | -0.168 | |
| Price To Book Ratio | 2.928 | 2.492 | 2.169 | 1.932 | 1.618 | |
| Price To Sales Ratio | 1.792 | 1.738 | 2.039 | 2.068 | 2.685 | |
| Price To Free Cash Flow Ratio | 10.490 | 22.690 | 9.881 | -13.726 | -28.570 | |
| Price To Operating Cash Flow Ratio | 8.546 | 16.681 | 8.344 | -20.964 | 174.721 | |
| Debt To Assets Ratio | 0.226 | 0.486 | 0.316 | 0.377 | 0.372 | |
| Debt To Equity Ratio | 0.601 | 1.456 | 0.624 | 0.846 | 0.801 | |
| Debt To Capital Ratio | 0.376 | 0.593 | 0.384 | 0.458 | 0.445 | |
| Long Term Debt To Capital Ratio | 0.363 | 0.589 | 0.384 | 0.458 | 0.444 | |
| Financial Leverage Ratio | 2.664 | 2.996 | 1.976 | 2.245 | 2.151 | |
| Working Capital Turnover Ratio | 2.184 | 1.735 | 1.573 | 1.321 | 1.326 | |
| Operating Cash Flow Ratio | 0.666 | 0.331 | 0.818 | -0.314 | 0.038 | |
| Operating Cash Flow Sales Ratio | 0.210 | 0.104 | 0.244 | -0.099 | 0.015 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.815 | 0.735 | 0.844 | 1.527 | -6.116 | |
| Debt Service Coverage Ratio | 5.085 | 2.495 | 3.797 | 1.377 | 1.297 | |
| Interest Coverage Ratio | 4.049 | 0.033 | 1.744 | -1.258 | -3.338 | |
| Short Term Operating Cash Flow Coverage Ratio | 10.726 | 6.980 | 139.952 | -36.709 | 3.908 | |
| Operating Cash Flow Coverage Ratio | 0.570 | 0.103 | 0.416 | -0.109 | 0.012 | |
| Capital Expenditure Coverage Ratio | 5.397 | 3.776 | 6.426 | -1.896 | 0.141 | |
| Dividend Paid And Capex Coverage Ratio | 5.221 | 3.446 | 5.908 | -1.726 | 0.139 | |
| Dividend Payout Ratio | 0.015 | -0.088 | 0.087 | -0.034 | -0.004 | |
| Enterprise Value Multiple | 7.828 | 24.511 | 9.916 | 35.640 | 246.307 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 51.0% | ▼-8.3% | ▼-5.5% |
| Ebit Margin | 13.1% | ▲13.9% | ▲15.0% |
| Ebitda Margin | 23.5% | ▲13.2% | ▲10.5% |
| Operating Profit Margin | 9.2% | ▲9.1% | ▲11.3% |
| Pretax Profit Margin | 10.8% | ▲14.5% | ▲17.7% |
| Continuous Operations Profit Margin | 8.9% | ▲11.9% | ▲13.9% |
| Net Profit Margin | 8.9% | ▲11.9% | ▲13.9% |
| Bottom Line Profit Margin | 8.0% | ▲11.3% | ▲13.4% |
| Current Ratio | 2.708 | ▼-0.017 | ▼-0.521 |
| Quick Ratio | 2.193 | ▲0.175 | ▼-0.240 |
| Solvency Ratio | 0.189 | ▲0.131 | ▲0.096 |
| Cash Ratio | 1.027 | ▲0.279 | ▲0.042 |
| Price To Earnings Ratio | 22.554 | ▲75.708 | ▲22.414 |
| Price To Earnings Growth Ratio | -0.052 | ▼-0.305 | ▼-0.226 |
| Forward Price To Earnings Growth Ratio | -0.052 | ▼-0.305 | ▼-0.226 |
| Price To Earnings Diluted Ratio | 23.777 | ▲76.931 | ▲23.269 |
| Price To Earnings Diluted Growth Ratio | -0.057 | ▼-0.309 | ▼-0.229 |
| Price To Book Ratio | 2.928 | ▲0.435 | ▲0.700 |
| Price To Sales Ratio | 1.792 | ▲0.054 | ▼-0.272 |
| Price To Free Cash Flow Ratio | 10.490 | ▼-12.200 | ▲10.337 |
| Price To Operating Cash Flow Ratio | 8.546 | ▼-8.135 | ▼-28.919 |
| Debt To Assets Ratio | 0.226 | ▼-0.260 | ▼-0.130 |
| Debt To Equity Ratio | 0.601 | ▼-0.855 | ▼-0.265 |
| Debt To Capital Ratio | 0.376 | ▼-0.217 | ▼-0.076 |
| Long Term Debt To Capital Ratio | 0.363 | ▼-0.227 | ▼-0.085 |
| Financial Leverage Ratio | 2.664 | ▼-0.332 | ▲0.257 |
| Working Capital Turnover Ratio | 2.184 | ▲0.449 | ▲0.556 |
| Operating Cash Flow Ratio | 0.666 | ▲0.336 | ▲0.358 |
| Operating Cash Flow Sales Ratio | 0.210 | ▲0.105 | ▲0.115 |
| Free Cash Flow Operating Cash Flow Ratio | 0.815 | ▲0.080 | ▲1.254 |
| Debt Service Coverage Ratio | 5.085 | ▲2.590 | ▲2.275 |
| Interest Coverage Ratio | 4.049 | ▲4.016 | ▲3.803 |
| Short Term Operating Cash Flow Coverage Ratio | 10.726 | ▲3.747 | ▼-14.245 |
| Operating Cash Flow Coverage Ratio | 0.570 | ▲0.467 | ▲0.371 |
| Capital Expenditure Coverage Ratio | 5.397 | ▲1.621 | ▲2.628 |
| Dividend Paid And Capex Coverage Ratio | 5.221 | ▲1.775 | ▲2.623 |
| Dividend Payout Ratio | 0.015 | ▲0.102 | ▲0.020 |
| Enterprise Value Multiple | 7.829 | ▼-16.682 | ▼-57.012 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.58B | $1.07B | $992.6M | $654.1M | $580.4M | |
| Enterprise value | $1.62B | $1.55B | $1.06B | $892.4M | $767.5M | |
| EV / Sales | 1.84x | 2.52x | 2.17x | 2.82x | 3.55x | |
| EV / Op. cash flow | 8.76x | 24.17x | 8.89x | -28.60x | 231.03x | |
| EV / Free cash flow | 10.75x | 32.87x | 10.52x | -18.73x | -37.78x | |
| EV / EBITDA | 7.83x | 24.51x | 9.92x | 35.64x | 246.31x | |
| Net debt / EBITDA | 0.19x | 7.59x | 0.60x | 9.52x | 60.03x | |
| Current ratio | 2.71x | 2.73x | 3.57x | 3.46x | 3.68x | |
| Income quality | 2.36x | -3.46x | 6.33x | 0.65x | -0.08x | |
| Graham number | $49 | — | $24 | — | — | |
| Graham net-net | -$17 | -$24 | -$3 | -$12 | -$14 | |
| Tax burden | 81.8% | 83.4% | 94.5% | 76.4% | 76.0% | |
| Interest burden | 82.7% | 481.8% | 42.5% | 181.0% | 127.0% | |
| Working capital | $475.0M | $334.0M | $374.3M | $244.8M | $234.2M | |
| Invested capital | $1.08B | $992.7M | $656.2M | $567.9M | $608.9M | |
| Return on assets | 5.4% | -1.4% | 2.1% | -6.3% | -5.5% | |
| Operating ROA | 6.0% | 0.1% | 5.6% | -4.6% | -6.5% | |
| Return on tangible assets | 8.7% | -2.7% | 2.8% | -10.0% | -9.5% | |
| Return on equity | 14.5% | -4.3% | 4.1% | -14.1% | -11.9% | |
| Return on invested capital | 5.6% | 0.0% | 5.8% | -4.1% | -4.4% | |
| Return on capital employed | 7.0% | 0.1% | 6.2% | -5.3% | -5.8% | |
| Earnings yield | 4.9% | -1.7% | 1.9% | -7.3% | -7.3% | |
| Free cash flow yield | 9.5% | 4.4% | 10.1% | -7.3% | -3.5% | |
| Capex / Op. cash flow | 18.5% | 26.5% | 15.6% | -52.7% | 711.6% | |
| Capex / Depreciation | 37.5% | 25.0% | 31.0% | 27.6% | 50.0% | |
| Capex / Sales | 3.9% | 2.8% | 3.8% | 5.2% | 10.9% | |
| SG&A / Sales | 36.0% | 40.6% | 33.2% | 39.2% | 39.0% | |
| R&D / Sales | 5.8% | 7.3% | 7.0% | 7.1% | 5.3% | |
| Stock comp / Sales | 4.3% | 4.8% | 4.2% | 4.6% | 4.9% | |
| Intangibles / Total assets | 37.6% | 46.9% | 26.2% | 36.8% | 41.7% | |
| Days sales outstanding | 116d | 132d | 122d | 191d | 217d | |
| Days payables outstanding | 53d | 67d | 74d | 77d | 83d | |
| Operating cycle | 237d | 331d | 345d | 468d | 513d | |
| Cash conversion cycle | 184d | 265d | 271d | 391d | 430d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+48.2%EV / Sales ▼-27.1%EV / EBITDA ▼-68.1%EV / Op. cash flow ▼-15.407Earnings yield ▲+0.067
Profitability
Return on equity ▲+0.188Return on assets ▲+0.069Return on invested capital ▲+0.056Return on capital employed ▲+0.069Operating ROA ▲+0.059Income quality ▲+5.821Tax burden ▼-0.016
Efficiency
Days sales outstanding ▼-15.586Days payables outstanding ▼-13.814Operating cycle ▼-94.445Cash conversion cycle ▼-80.631Capex / Sales ▲+0.011R&D / Sales ▼-0.014
Balance-sheet strength
Current ratio ▼-0.017Net debt / EBITDA ▼-7.401Working capital ▲+141001000.000Invested capital ▲+86796000.000Intangibles / Total assets ▼-0.093
Change over 5 years
Valuation
Market cap ▲+172.7%EV / Sales ▼-48.3%EV / EBITDA ▼-96.8%EV / Op. cash flow ▼-222.273Earnings yield ▲+0.123
Profitability
Return on equity ▲+0.264Return on assets ▲+0.110Return on invested capital ▲+0.100Return on capital employed ▲+0.128Operating ROA ▲+0.124Income quality ▲+2.442Tax burden ▲+0.058
Efficiency
Days sales outstanding ▼-100.908Days payables outstanding ▼-30.533Operating cycle ▼-276.604Cash conversion cycle ▼-246.071Capex / Sales ▼-0.071R&D / Sales ▲+0.006
Balance-sheet strength
Current ratio ▼-0.968Net debt / EBITDA ▼-59.844Working capital ▲+240767000.000Invested capital ▲+470568000.000Intangibles / Total assets ▼-0.041
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-24 ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors – Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026.
- 2026-08-20 Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP Aurora Investment Counsel bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) in the undefined quarter, according to its most recent filing with the SEC. The fund bought 26,890 shares of the specialty pharmaceutical company''s stock, valued at approximately $2,226,000. Aurora Investment Counsel owned 0.12% of ANI Pharmaceuticals at the end of
- 2026-08-14 ANIP''s Cortrophin Guidance Cut Raises the Bar for Second-Half Growth Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals'' second-half execution as the drug must deliver a sharper growth ramp.
- 2026-08-14 Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? ANI Pharmaceuticals'' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
- 2026-08-10 ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
- 2026-08-07 ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
- 2026-08-07 Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 2026-08-07 ANI Pharmaceuticals Q2 Earnings Call Highlights ANI Pharmaceuticals NASDAQ: ANIP reported record second-quarter revenue and adjusted EBITDA as growth in its Cortrophin Gel rare-disease franchise and generics business lifted results, while the company modestly reduced its full-year Cortrophin revenue outlook to reflect first-half performance.
- 2026-08-07 ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $1.8 per share a year ago.
- 2026-08-07 ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin ® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year Quarterly GAAP net income available to common shareholders of $24.7 million; Quarterly adjusted non-GAAP EBITDA of $71.6 million, an increase of 32.4% year-over-year Diluted GAAP income per share of $1.05 and adjusted non-GAAP diluted earnings per share of $2.21 Reaffirming 2026 guidance for total net revenue of $1,080 - $1,140 million and adjusted non-GAAP EBITDA of $285 - $300 million PRINCETON, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2026.